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a b s t r a c t
INTRODUCTION: Adrenal cortical carcinoma (ACC) is a very rare type of tumor that generally has a poor
prognosis. Little has been reported on repeated liver resections with recurrent metastasis still conﬁned
to the liver. In this report, we describe a case of functioning ACC in a 65-year-old woman with 2 liver
metastases of the ACC (at 1.5 and 4 years) after the right adrenalectomy.
PRESENTATIONOF CASE:A 65-year-oldwomanwas referred to our hospital based on a suspicion of hyper-
aldosteronism. Abdominal computed tomography revealed a lesion at the right adrenal gland; therefore,
we performed right adrenalectomy and subsequently diagnosed the lesion as ACC. However, follow-up
computed tomography at 1.5 and 4 years after the right adrenalectomy revealed liver metastasis of ACC;
liver resection was performed for both metastases.
DISCUSSION: Complete surgical resection is the established approach for the treatment of ACC. The prog-
nosis of ACC is usually dismal, and recurrence rates of up to 85% have been reported. However, the
appropriate treatment for recurrent ACC is not well established, and the effectiveness of other modali-
ties, such as chemotherapy and radiotherapy, is not proven. Therefore, surgical resection may currently
be the most appropriate treatment modality, as the patient achieved a disease-free interval of 2.5 years
after the ﬁrst liver resection.
CONCLUSION: In selected patients with recurrent or metastatic ACC, resection is likely to be associated
withprolonged survival.However, a full cure is generallynot achievable, andamultidisciplinary approach
is likely needed to achieve long-term disease-free status and survival.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Adrenal cortical carcinoma(ACC) is avery rare tumor,withahet-
erogeneous presentation and an incidence of 0.7–2.0 cases/million
people/year [1]. Although ACC can develop at any age, a bimodal
age distribution has been observed, with peaks before the age of 5
years and at the age of 40–59 years [2]. Adrenal tumors are classi-
ﬁed as functioning and non-functioning tumors. Functional tumors
occur in an estimated 40–60% of adult patients, with the majority
of these patients havingCushing’s syndromewithhypercortisolism
[3]. However, the pathogenesis of ACC remains poorly understood.
Unfortunately, the prognosis for ACC is generally poor, with a
5-year overall survival (OS) of 37% [4]. Although ACC is potentially
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curable in the early stages, only approximately 30% of these malig-
nancies are conﬁned to the adrenal glandwhen they are diagnosed,
as these tumors tend to be found years after their genesis. There-
fore, these tumors have the opportunity for both near and distant
metastases, and this aggressive behavior leads to their poor prog-
nosis [5]. Common sites ofmetastases include the liver (47%), lungs
(43%), and lymph nodes and bone (25%) [2], although the optimal
management for recurrent ACC is currently not well established.
Due to poor response rates to systemic treatments, surgery remains
the best treatment modality for ACC, and complete resection offers
the greatest hope for long-term survival [6].
In this report, we present a case of functioning ACC in a 65-
year-old woman who initially underwent right adrenal surgical
resection, and subsequently experienced recurrent liver metas-
tases (at 1.5 and 4 years after the initial resection) that were
surgically resected. We report this case, as little has been reported
on repeated liver resectionswith recurrentmetastasis still conﬁned
to the liver.
http://dx.doi.org/10.1016/j.ijscr.2015.02.041
2210-2612/© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Computed tomography of the 7 cm right adrenal mass (arrow).
2. Presentation of case
A 65-year-old Japanese woman presented to her family
physician complaining of persistent pedal edema over a 2-
month period. Blood tests revealed decreased potassium levels
(2.2mEq/L) and a urine test revealed proteinuria; therefore,
she was referred to our hospital. Central obesity, moon facies,
and stretch marks were observed in the physical examination,
and detailed questions regarding her medical history revealed
previous hypertension. However, her social history was unre-
markable, and she reported no family medical history. Her blood
pressure was 160/80mmHg, and the results of liver and renal
function tests with a complete blood count were within the
normal limits. Her serum potassium levels were (2.6mEq/L),
and arterial blood gas examination indicated metabolic alkalo-
sis (pH 7.47, pCO2 =58.6mmHg, HCO3 =42.1mEq/L). Abdominal
computed tomography (CT) revealed a 7.0 cm lesion at the right
adrenal gland (Fig. 1), and hormone testing revealed excessive
serum cortisol (with loss of the diurnal pattern), elevated urine
free cortisol, and a non-suppressible response to the dexametha-
sone test (Table 1). Therefore,weperformed surgical removal of the
right adrenal tumor, and histopathological examination revealed
large eosinophilic cells with highly atypical nuclei and more than 5
mitoses per 50 high-power ﬁelds (Fig. 2). Based on these ﬁndings,
the patient was diagnosed with ACC.
She had an uneventful postoperative period, and her blood
pressure and serum potassium levels returned to normal levels
within a few days. Furthermore, 1 year after the right adrenalec-
tomy,hormone tests revealednormalpatterns.However, follow-up
abdominal CT at 1.5 year after the initial surgery revealed a solitary
hepatic lesion (26mm in diameter) in segment 7. Magnetic reso-
nance imaging of the liver conﬁrmed the presence of the 26mm
mass in segment 7 and also revealed a 10mm mass in segment 5
(Fig. 3). Liver needle biopsy was subsequently performed, which
Table 1
Results of the hormone tests.
Hormone Concentration Reference
Basal hormones – –
09:00 AM serum cortisol(g/dl) 14.8 3.7–19.4
21:00 PM serum cortisol(g/dl) 16.1 3.7–19.4
Urinary free cortisol(g/day) 351.0 176.0–4.3
Plasma renin activity (pg/ml) 0.5 0.3–2.9
Plasma aldosterone(pg/ml) 283 29–159
Urinary freealdosterone(g/day) 43 <10
Serum DHEA-S(mol/l) 72 12–133
High-dose dexamethasone test – –
Serum cortisol(g/dl) 17.5 3.7–19.4
revealed metastatic carcinoma; therefore, the patient underwent
the right hepatectomy. Histopathological assessment of the lobec-
tomy specimens revealed that the mass was liver metastasis of the
ACC. Follow-up abdominal CT at 4 year after the right adrenalec-
tomy revealed another solitary hepatic lesion (29mm in diameter)
in segment 3. Therefore, the patient underwent partial resection
of segment 3, and histopathological assessment of the specimens
revealed that the mass was liver metastasis of the ACC (Fig. 4).
The postoperative course was uneventful, and the patient was
discharged 14 days after surgery. At the 6-month follow-up, she
appeared healthy without clinical evidence of recurrent disease.
3. Discussion
ACC is a very rare malignancy, with an incidence of 0.7–2.0
cases/million people/year [1], and these tumors can be classiﬁed
as functioning and non-functioning tumors. Functioning tumors
occur in an estimated40–60%of all adult patients, and these tumors
may secrete excessive glucocorticoids (e.g., Cushing’s syndrome),
mineralocorticoids, and their downstream products, including
androgens (virilization), estrogens (feminization), and aldosterone,
which can cause hypertension [3,7]. In contrast, non-functioning
tumors may present with pain or distention in the abdomen due
to mass effect, weight loss, weakness, fever, and myalgia, or may
be discovered incidentally during un-related radiographic imag-
ing (e.g., abdominal CT or magnetic resonance imaging) [8,9]. In
this case, the patient was referred to our hospital based on a sus-
picion of hyperaldosteronism, due to pedal edema, hypokalemia,
and hypertension, and Cushing’s syndrome was conﬁrmed by the
loss of the diurnal cortisol patterns and elevated urine levels of free
cortisol.
Complete surgical resection is the established approach for
treating ACC, and previous reports have demonstrated that the
effectiveness of other modalities is limited [10,11]. However, even
when the tumors are localized, the prognosis for ACC is usually dis-
mal, and recurrence rates of up to 85% have been reported [12,13].
Furthermore, the 5-year OS for patients with metastatic ACC is
<20%, with a median survival of between 6 and 20 months [14,15].
However, the management of recurrent ACC is not as well estab-
lished in the literature. The currently available chemotherapies
have limited efﬁciency, including the traditional and widely-used
adrenolytic agent mitotane, which has a doubtful effect on sur-
vival [16,17]. Although radiation therapy has been used to palliate
bony metastases, ACC is generally considered radioresistant, and
the effectiveness of radiotherapy for ACC remains unclear [18]. In
light of these ﬁndings, surgery remains the best treatment modal-
ity for ACC, and complete resection is considered the best hope for
long-term survival [6]. However, data regarding the effectiveness
of surgery in themanagement of recurrent ACC remain scarce. Nev-
ertheless, due to the doubtful efﬁcacy of other modalities, surgery
should be considered for the treatment of recurrent or metastasis
ACC if complete resection is possible. For example, in the present
case, the patient achieved a disease-free interval (DFI) of 2.5 years
after the ﬁrst liver resection.
To achieve prolonged DFI and improve the prognosis, R0-
resection has been suggested. For example, Datrice et al. have
reported 57 patients who underwent 116 procedures for recur-
rent or metastatic disease, and the authors noted that the median
OS for patients with a DFI of <12 months was 1.7 years, com-
pared to 6.6 years for patients with a DFI of >12 months [6]. In
another study of 154 patients with their ﬁrst recurrence after ini-
tial radical resection of ACC, patients who had a DFI of >12 months
and underwent R0-resection of the recurrent tumors had the best
prognosis (median progression-free survival, 24 months; median
OS, >60 months) [19]. The authors concluded that, in selected
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Fig. 2. The resected specimen from the ﬁrst recurrence. (A) Macroscopic ﬁndings reveal a light-gray 7.7 cm mass. (B) Microscopic ﬁnding reveal large eosinophilic cells with
highly atypical nuclei, and more than 5 mitoses per 50 high-power ﬁelds (hematoxylin and eosin, ×2).
Fig. 3. Magnetic resonance imaging of the liver reveals (A) a 10mm mass in segment 5, and (B) a 26mm mass in segment 7.
Fig. 4. The resected specimen from the second recurrence. (A) Macroscopic ﬁndings reveal a light-gray 2.8 cm mass. (B) Microscopic ﬁnding reveal the features of the primary
adrenal cortical tumor, which was composed of large eosinophilic cells with highly atypical nuclei (hematoxylin and eosin, ×40). Immunohistochemical staining reveals
that the tumor cells were not immunoreactive for hepatocyte parafﬁn 1 (a monoclonal anti-hepatocyte antibody) (C), although the cells were diffusely immunoreactive for
inhibin ˛ (D).
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patients with recurrent or metastasis ACC, resection is associated
with prolonged survival. In the present case, the patient’s prognosis
appeared good, and resection should have been recommended, as
no predictors of repeat resection were present. However, as there
were 2.5 years between the ﬁrst and second recurrence, we were
able to choose surgical resection for the second recurrence. Never-
theless, it is important to note that a full cure after hepatic resection
is generally not achievable, and Gaujoux et al. have reported that
all 28 patients who underwent resection for ACC liver metasta-
sis subsequently developed recurrent disease [20]. In the present
case, the patient experienced recurrent metastasis within the liver,
whichwas treated surgically via repeat hepatectomy.However, she
achieved aDFI of 2.5 years after the ﬁrst resection for livermetasta-
sis; therefore, we believe that this outcome indicates the efﬁcacy of
surgical resection in similar cases. As our follow-up period was rel-
atively short, special attention should be paid to the disease course
after a second surgical resection, and a multidisciplinary approach
is likely needed to achieve long-term disease-free status and sur-
vival.
4. Conclusion
We report the case of a 65-year-old Japanese woman with two
recurrent livermetastasesofACC (1.5 and4years after right adrenal
surgical resection) that were both surgically resected. Reports on
repeated liver resectionswith recurrentmetastasis still conﬁned to
the liver are scare. In selected patients with recurrent or metasta-
sis ACC, resection is likely to be associated with prolonged survival.
However, as a full cure is generally not achievable, a multidisci-
plinary approach is likely needed to achieve long-termdisease-free
status and survival.
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